In our latest episode, Adam Tubero digs into one of the more well-known Psychedelic biotech companies in the industry, Cybin (CYBN). Tune in as we take a closer look at Cybin’s financials, the development of CYB003 – which has the potential to effectively treat major depressive disorder (MDD) and alcohol use disorder (AUD) – and…

You must have PRO to access this content.

Become a Pro
Login with Neuly